Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × Trastuzumab × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02291289 2024-05-06

MODUL

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03457896 2022-03-31

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Intestinal Neoplasms, Colorectal Neoplasms

NCT04380012 2021-07-15

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03185988 2019-07-19

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Colorectal Neoplasms

NCT03225937 2018-10-30

HERACLES

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT00006015 2013-05-03

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00003995 2013-02-08

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms